UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

          Date of Report (Date of earliest event reported): May 4, 2005

                           ARIAD Pharmaceuticals, Inc.
             (Exact name of registrant as specified in its charter)


        Delaware                  0-21696               22-3106987
(State or other jurisdiction     (Commission          (I.R.S. Employer
    of incorporation)            File Number)         Identification No.)


              26 Landsdowne Street, Cambridge, Massachusetts 02139
               (Address of principal executive offices) (Zip Code)


       Registrant's telephone number, including area code: (617) 494-0400


                                 Not Applicable
          (Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|  Written communications pursuant to Rule 425 under the Securities Act
     (17 CFR 230.425)

|_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17 CFR 240.14a-12)

|_|  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

|_|  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))


ITEM 2.02  Results of Operations and Financial Condition

           On May 4, 2005, ARIAD Pharmaceuticals, Inc. announced consolidated
           financial results for the quarter ended March 31, 2005. A copy of
           the press release is furnished pursuant to this Item 2.02 as
           Exhibit 99.1 to this Current Report on Form 8-K.

ITEM 8.01  Other Events.

           In its press release dated May 4, 2005, ARIAD Pharmaceuticals, Inc.
           provided an update on progress towards achievement of 2005 goals
           under the headings "Sarcoma Market Highlights", "Upcoming
           Scientific Meetings" and "Upcoming Investor Meetings". The
           Company hereby incorporates such information by reference into
           this Item 8.01 of this Current Report on Form 8-K.

ITEM 9.01  Financial Statements and Exhibits.

           (c)    Exhibits

                  Exhibit
                  Number            Description
                  ------            -----------
                  99.1              Press release dated May 4, 2005.

                  The portions of the Press Release incorporated by reference
                  into Item 8.01 of this Current Report on Form 8-K are
                  being filed pursuant to Item 8.01. The remaining
                  portions of the Press Release are being furnished
                  pursuant to Item 2.02 of this Current Report on Form
                  8-K and shall not be deemed "filed" for purposes of
                  Section 18 of the Securities Exchange Act of 1934 (the
                  "Exchange Act") or otherwise subject to the liabilities
                  of that Section, nor shall it be deemed incorporated by
                  reference in any filing under the Securities Act of
                  1933 or the Exchange Act.

                                       2


                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                             ARIAD Pharmaceuticals, Inc.

                             By:     /s/ Edward M. Fitzgerald
                                     -------------------------------------------
                                     Edward M. Fitzgerald
                                     Senior Vice President and Chief Financial
                                     Officer

Date:    May 4, 2005

                                       3

                                  EXHIBIT INDEX
                                  -------------

Exhibit
Number            Description
------            -----------
 99.1             Press release dated May 4, 2005.

                                       4